Interim results of a phase II study of fluorouracil (FU), leucovorin (LV), and nanoliposomal irinotecan (nal-IRI) in previously treated advanced biliary tract cancer (NAPOLI-2)

被引：0
|
作者：
Weinberg, B. [1 ]
He, A. [1 ]
Tan, B. [2 ]
Turk, A. [3 ]
Noel, M. [1 ]
Marshall, J. [1 ]
Sung, M. [4 ]
Wang, H. [1 ]
Ferguson, C. [1 ]
Swanson, N. [1 ]
Pedersen, K. [2 ]
机构：
[1] Georgetown Univ, Ruesch Ctr Cure Gastrointestinal Canc, Lombardi Comprehens Canc Ctr, Washington, DC USA
[2] Washington Univ, Sch Med, St Louis, MO USA
[3] Indiana Univ Sch Med, Dept Hematol Oncol, Indianapolis, IN USA
[4] Tisch Canc Inst Mt Sinai, New York, NY USA
来源：
ANNALS OF ONCOLOGY | 2023年 / 34卷
关键词：
D O I：
10.1016/j.annonc.2023.04.287
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P-231
引用
收藏
页码：S97 / S98
页数：2
相关论文
共 50 条
  • [31] A randomised phase II study comparing irinotecan (IRI) plus leucovorin (LV) and 5-fluorouracil (5FU) versus IRI-LV-5FU followed be oxaliplatin (OXA) plus LV-5FU in patients with previously untreated metastatic colorectal cancer (CRC).
    Kalofonos, H. P.
    Papakostas, P.
    Aravantinos, G.
    Papadimitriou, C.
    Pentheroudakis, G.
    Varthalitis, I.
    Tsavdaridis, D.
    Syrigos, K.
    Kosmidis, P.
    Fountzilas, G.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 166S - 166S
  • [32] Phase II trial of oxaliplatin, 5-fluorouracil (5-FU) and leucovorin (LV) for advanced biliary tract adenocarcinoma.
    Porschen, R
    Nehls, O
    Bermann, A
    Burkart, C
    Gregor, M
    GASTROENTEROLOGY, 1999, 116 (04) : A487 - A487
  • [33] PRELIMINARY PHASE II RESULTS OF OXALIPLATIN, 5-FU AND LEUCOVORIN IN ADVANCED BILIARY TRACT CANCER
    Lee, N.
    Lee, S.
    Kim, K.
    Won, J.
    Kim, H.
    Kim, S.
    Kim, C.
    Park, S.
    Hong, D.
    Moon, J.
    Kim, H.
    Bae, S.
    Lee, K.
    Park, S.
    Park, H.
    ANNALS OF ONCOLOGY, 2010, 21 : 98 - 98
  • [34] CA19-9 decrease and overall survival (OS) in the NAPOLI-1 trial of liposomal irinotecan (nal-IRI) 6 5-fluorouracil and leucovorin (5-FU/LV) in metastatic pancreatic ductal adenocarcinoma (mPDAC) previously treated with gemcitabine-based therapy
    Chen, L-T.
    Wang-Gillam, A.
    Shan, Y-S.
    Mercade, T. Macarulla
    Blanc, J. F.
    Hubner, R.
    Chiu, C-F.
    Schwartsmann, G.
    Siveke, J.
    Belanger, B.
    de Jong, F.
    Mamlouk, K.
    von Hoff, D.
    ANNALS OF ONCOLOGY, 2017, 28
  • [35] Subgroup analysis by prior non-liposomal irinotecan therapy in NAPOLI-1: A phase 3 study of nal-IRI ±5-fluorouracil/leucovorin in patients with metastatic pancreatic ductal adenocarcinoma previously treated with gemcitabine-based therapy
    Jean-Frederic, Blanc
    Richard, Hubner
    Li Chung-Pin
    Andrea, Wang-Gillam
    Gyorgy, Bodoky
    Andrew, Dean
    Shan Yan-Shen
    Gayle, Jameson
    Teresa, Macarulla
    Kyung-Hun, Lee
    David, Cunningham
    Chiu Chang-Fang
    Gilberto, Schwartsmann
    Fadi, Braiteh
    Daniel, Von Hoff
    Chen Li-Tzong
    Khalid, Mamlouk
    Parul, Bhargava
    Floris, de Jong
    Jens, Siveke
    ANNALS OF ONCOLOGY, 2017, 28
  • [36] Nal-IRI with 5-fluorouracil and leucovorin or gemcitabine plus cisplatin in advanced biliary tract cancer, a phase 2 study of the AIO hepatobiliary and YMO cancer groups (NIFE-AIO-YMO HEP-0315) - updated survival and QoL results
    Perkhofer, Lukas
    Modest, Dominik Paul
    Sinn, Marianne
    Striefler, Jana Kaethe
    Opitz, Bernhard
    Goetze, Thorsten O.
    Gallmeier, Eike
    Angermeier, Stefan
    von Weikersthal, Ludwig Fischer
    Jacobasch, Lutz
    Waldschmidt, Dirk
    Niedermeier, Michael
    Sohm, Michael
    Sookthai, Disorn
    Schaaf, Marina
    Hinke, Axel
    Seufferlein, Thomas
    Ettrich, Thomas J.
    ONCOLOGY RESEARCH AND TREATMENT, 2024, 47 : 66 - 66
  • [37] Preliminary phase II results of oxaliplatin, 5-FU, and leucovorin in advanced biliary tract cancer.
    Lee, S.
    Kim, H.
    Kim, S.
    Kim, C.
    Bae, S.
    Lee, K.
    Yun, J.
    Hong, D.
    Park, H.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [38] Nal-IRI with 5-fluorouracil (5-FU) and leucovorin or gemcitabine plus cisplatin in advanced biliary tract cancer - the NIFE trial (AIO-YMO HEP-0315) an open label, non-comparative, randomized, multicenter phase II study
    L. Perkhofer
    A. W. Berger
    A. K. Beutel
    E. Gallmeier
    S. Angermeier
    L. Fischer von Weikersthal
    T. O. Goetze
    R. Muche
    T. Seufferlein
    T. J. Ettrich
    BMC Cancer, 19
  • [39] Nal-IRI with 5-fluorouracil (5-FU) and leucovorin or gemcitabine plus cisplatin in advanced biliary tract cancer - the NIFE trial (AIO-YMO HEP-0315) an open label, non-comparative, randomized, multicenter phase II study
    Perkhofer, L.
    Berger, A. W.
    Beutel, A. K.
    Gallmeier, E.
    Angermeier, S.
    von Weikersthal, L. Fischer
    Goetze, T. O.
    Muche, R.
    Seufferlein, T.
    Ettrich, T. J.
    BMC CANCER, 2019, 19 (01)
  • [40] Preliminary results of a multicenter phase II study of imatinib and fluorourcail/leucovorin (FU/LV) in patients with unresectable or metastatic gallbladder or biliary tract cancer
    Schuette, K.
    Moehler, M.
    Kettner, E.
    Al-Batran, S.
    Hegewisch-Becker, S.
    Steffens, C.
    Pustowka, A.
    Goekkurt, E.
    Ehninger, G.
    Stoehlmacher, J.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
12345